Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS INCCNST · Entity 137050 | 10% owner | August 22, 2018 | August 24, 2018 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | 10% owner | August 30, 2018 | September 04, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONSTELLATION PHARMACEUTICALS INC
Report date August 22, 2018 · Filed August 24, 2018
Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., Levin Mark J, STARR KEVIN P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,034,083 |
Reported balance
After 2018-08-22 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-08-22 · Other · Acquired 51,032 · Balance 3,034,083 F1: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2021-05-24 | Direct | 0 |
Reported balance
After 2018-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-08-22 · Other · Disposed 51,032 · Balance 0 F2: The warrant was fully exercisable upon grant. F1: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares
F2: The warrant was fully exercisable upon grant.
RHYTHM PHARMACEUTICALS, INC.
Report date August 30, 2018 · Filed September 04, 2018
Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., STARR KEVIN P, Tepper Robert I, Levin Mark J
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,981,437 |
Reported balance
After 2018-08-30 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2018-08-30 · Other · Disposed 1,000,000 · Balance 2,981,437 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 99,105 |
Reported balance
Holding disclosure · report date 2018-08-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 99,105 F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 99,105 |
Reported balance
Holding disclosure · report date 2018-08-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 99,105 F4: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 99,105 |
Reported balance
Holding disclosure · report date 2018-08-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 99,105 F5: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
F4: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
F5: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CytomX Therapeutics, Inc.
Report date October 18, 2017 · Filed October 19, 2017
Jointly reported with THIRD ROCK VENTURES LP, Third Rock Ventures GP, L.P., Levin Mark J, STARR KEVIN P, Tepper Robert I
Section 16 reporting ended · disclosed 2017-10-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,320,348 |
Reported balance
After 2017-10-18 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2017-10-18 · Other · Disposed 1,000,000 · Balance 3,320,348 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 116,927 |
Reported balance
Holding disclosure · report date 2017-10-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 116,927 F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 145,286 |
Reported balance
Holding disclosure · report date 2017-10-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 145,286 F4: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. |
| Common StockSEC Table I · non-derivative | Direct | 85,509 |
Reported balance
Holding disclosure · report date 2017-10-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 85,509 F5: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
F3: These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
F4: These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above.
F5: These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 30, 2018 Filed Sep 4, 2018 16:06 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-023708 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,981,437 F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), Third Rock Ventures GP, L.P. ("TRV GP") and TRV GP, LLC ("TRV GP LLC"), TRV distributed on August 30, 2018, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP, the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP LLC. The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 16:05 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | OtherWarrant (right to buy) · Derivative | 51,032 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0000899243-18-023212 · doc4.xml · derivative · entry 2 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,032 shares Expires 2021-05-24 F2 · derivative.exercise_date: The warrant was fully exercisable upon grant. F1 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 16:05 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | OtherCommon Stock | 51,032 | $1.55 | $79,099.60 |
DisclosureSEC source: 0000899243-18-023212 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,034,083 F1 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries F Preferred Stock · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · derivative · entry 8 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,840 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E-1 Preferred Stock · Derivative | 3,107,930 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · derivative · entry 7 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 282,308 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries E Preferred Stock · Derivative | 2,285,640 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · derivative · entry 6 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 266,934 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries D Preferred Stock · Derivative | 1,086,411 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · derivative · entry 5 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries B Preferred Stock · Derivative | 10,650,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · derivative · entry 4 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 967,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionSeries A Preferred Stock · Derivative | 11,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · derivative · entry 3 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 999,180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.exercise_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F1 · derivative.expiration_date: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | PurchaseCommon Stock | 266,667 | $15.00 | $4,000,005.00 |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · nonDerivative · entry 2 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,983,051 F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| July 23, 2018 Filed Jul 24, 2018 19:19 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | ConversionCommon Stock | 2,705,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-020534 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,716,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On July 23, 2018, the Series A, Series B, Series D, Series E-1 and Series F Preferred Stock converted into Common Stock on a 11.009-for-one basis, and the Series E Preferred Stock converted into Common Stock on a 8.56256-for-one basis, upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B, Series C, Series E, Series E-1 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date. F2 · ownership.direct: These securities are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares Read SEC document |
| October 18, 2017 Filed Oct 19, 2017 16:00 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-024464 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,320,348 F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on October 18, 2017, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionSeries A-1 Junior Preferred Stock · Derivative | 26,868,642 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-024006 · doc4.xml · derivative · entry 3 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,930,059 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionSeries A Convertible Preferred Stock · Derivative | 9,479,502 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-024006 · doc4.xml · derivative · entry 2 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,033,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| October 10, 2017 Filed Oct 11, 2017 16:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionCommon Stock | 3,963,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-024006 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,981,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the total number of shares of Common Stock received by Third Rock Ventures, L.P. ("TRV") upon conversion of the Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock of the Issuer in connection with the closing of the Issuer's initial public offering. F2 · price: The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock converted into Common Stock on a 9.17-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Convertible Preferred Stock and Series A-1 Junior Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| July 13, 2017 Filed Jul 13, 2017 20:07 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | OtherCommon Stock | 850,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-018238 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,320,348 F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on July 13, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on July 13, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| March 27, 2017 Filed Mar 27, 2017 19:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 650,000 | $18.00 | $11,700,195.00 |
DisclosureSEC source: 0000899243-17-008731 · doc4.xml · nonDerivative · entry 2 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,170,348 F2 · price: This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.45, inclusive. Each of the reporting persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F1 · ownership.direct: These shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 19:28 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | SaleCommon Stock | 1,000,000 | $17.00 | $17,000,200.00 |
DisclosureSEC source: 0000899243-17-008731 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,820,348 F1 · ownership.direct: These shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| March 15, 2017 Filed Mar 16, 2017 17:30 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | OtherCommon Stock | 850,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-007785 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,820,348 F1 · kind: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on March 15, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on March 15, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 16:05 UTC | CytomX Therapeutics, Inc. CTMX · Entity 5124 | OtherCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-033012 · doc4.xml · nonDerivative · entry 1 THIRD ROCK VENTURES LP · CIK 0001408591 · 10% owner Third Rock Ventures GP, L.P. · CIK 0001578976 · 10% owner TRV GP, LLC · CIK 0001578973 · 10% owner LEVIN MARK J · CIK 0001180428 · 10% owner STARR KEVIN P · CIK 0001192603 · 10% owner TEPPER ROBERT I · CIK 0001192595 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,670,348 F1 · kind: On November 7, 2016, Third Rock Ventures, L.P. ("TRV") distributed, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On November 7, 2016, Third Rock Ventures, L.P. ("TRV") distributed, for no consideration, 1,000,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.